Eikon Therapeutics (EIKN) Q4 2025 earnings summary

Executive summary

• Completed upsized IPO in February 2026, raising $381 million in gross proceeds to strengthen the balance sheet and fund operations into 2H 2027.

• Advanced multiple clinical programs, including completion of enrollment for a Phase 2 trial in stage 4 non-small cell lung cancer and progress in PARP1 and WRN inhibitor pipelines.

• Appointed David W. Meline, former CFO of Moderna and Amgen, as independent director in December 2025.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $336.0 million as of December 31, 2025.

• R&D expenses rose 21% year-over-year to $65.2 million in Q4 2025 and 22% to $250.3 million for the full year, driven by clinical trial expansion and new headquarters costs.

• G&A expenses increased 29% in Q4 2025 and 59% for the full year, mainly due to asset impairments, compensation, and new facility expenses.

• Net loss attributable to common stockholders was $79.7 million for Q4 2025 and $333.6 million for the full year, compared to $64.9 million and $243.8 million in the prior-year periods.

Outlook and guidance

• Current cash position, including IPO proceeds, expected to fund operations into the second half of 2027.

• Anticipates comprehensive Phase 2 data for EIK1001 in non-small cell lung cancer in 2H 2026.

• Plans to initiate new clinical cohorts and trials for PARP1 and WRN inhibitor programs in 2026.